Where can I buy shares of bio?
BIO: Lowering target price to $614.00BIO-RAD LABORATORIES-A has an Investment Rating of BUY; a target price of $614.000000; an Industry Subrating of High; a …
What are analysts'target prices for Translate Bio's stock?
Apr 03, 2022 · Bio-Rad Laboratories' stock was trading at $345.79 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, BIO shares have increased by 55.5% and is now trading at $537.79. View which stocks have been most impacted by COVID-19.
What is the price targets for Bio-Rad Laboratories'stock?
Bio-Rad Laboratories started at hold with $195 stock price target at Deutsche Bank Jan. 18, 2017 at 8:44 a.m. ET by Tomi Kilgore SEC charges Bio-Rad Laboratories with bribery violations
What is Translate Bio's (TBIO) profit margin?
Mar 29, 2022 · 4 brokerages have issued 12-month price targets for Translate Bio's stock. Their forecasts range from $38.00 to $38.00. On average, they expect Translate Bio's stock price to reach $38.00 in the next twelve months. This suggests a possible upside of …
Is BIO good stock to buy?
Bio-Rad Laboratories Inc finds support from accumulated volume at $554.27 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested. This stock is usually traded at a good volume, and with minor daily changes, the risk is considered to be low.
Why is BIO going down?
Shares in Bio-Rad dropped 16.8 percent for the five-day trading period ended Tuesday. The firm's shares took a hit due to an underwhelming financial forecast during its fourth-quarter conference call last week (see related article, this issue), and a drop in stocks across the board.
Is BIO a buy Zacks?
See rankings and related performance below. The VGM Score are a complementary set of indicators to use alongside the Zacks Rank....Momentum Scorecard. More Info.Zacks RankDefinitionAnnualized Return1Strong Buy24.93%2Buy18.44%3Hold9.99%4Sell5.61%2 more rows
Does Bio-Rad stock pay dividends?
BIO does not currently pay a dividend.Apr 8, 2022
Is Bluebird Bio a good stock to buy?
bluebird bio has received a consensus rating of Hold. The company's average rating score is 2.07, and is based on 1 buy rating, 11 hold ratings, and 2 sell ratings.
Is Bluebird Bio stock a buy?
bluebird bio finds support from accumulated volume at $4.47 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested. This stock has average movements during the day and with good trading volume, the risk is considered to be medium.
Is Bio Rad undervalued?
According to the company's typical P/E ratio relation to the S&P 500's P/E ratio, BIO is undervalued.Dec 1, 2020
Is Bio Rad public?
Bio-Rad holds its Initial Public Offering and sells 40,000 shares at $3.50 a share. The company opens its first international office in Munich.
Is Bio-Rad Laboratories a buy right now?
2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Bio-Rad Laboratories in the last year. There are currently 2 buy...
How has Bio-Rad Laboratories' stock been impacted by COVID-19?
Bio-Rad Laboratories' stock was trading at $345.79 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organiza...
When is Bio-Rad Laboratories' next earnings date?
Bio-Rad Laboratories is scheduled to release its next quarterly earnings announcement on Thursday, May 5th 2022. View our earnings forecast for Bi...
How were Bio-Rad Laboratories' earnings last quarter?
Bio-Rad Laboratories, Inc. (NYSE:BIO) posted its quarterly earnings data on Thursday, February, 10th. The medical research company reported $3.21 e...
What guidance has Bio-Rad Laboratories issued on next quarter's earnings?
Bio-Rad Laboratories issued an update on its FY 2022 earnings guidance on Thursday, February, 24th. The company provided earnings per share guidanc...
What price target have analysts set for BIO?
2 brokers have issued twelve-month price objectives for Bio-Rad Laboratories' shares. Their forecasts range from $800.00 to $930.00. On average, th...
Who are Bio-Rad Laboratories' key executives?
Bio-Rad Laboratories' management team includes the following people: Norman D. Schwartz , Chairman, President & Chief Executive Officer Andrew J....
What is Norman Schwartz's approval rating as Bio-Rad Laboratories' CEO?
325 employees have rated Bio-Rad Laboratories CEO Norman Schwartz on Glassdoor.com . Norman Schwartz has an approval rating of 84% among Bio-Rad L...
Who are some of Bio-Rad Laboratories' key competitors?
Some companies that are related to Bio-Rad Laboratories include Thermo Fisher Scientific (TMO) , Illumina (ILMN) , Agilent Technologies (A) , M...
Is Translate Bio a buy right now?
7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Translate Bio in the last twelve months. There are curre...
How were Translate Bio's earnings last quarter?
Translate Bio, Inc. (NASDAQ:TBIO) posted its quarterly earnings results on Wednesday, August, 4th. The company reported $0.21 earnings per share (E...
What price target have analysts set for TBIO?
7 equities research analysts have issued 1-year price targets for Translate Bio's stock. Their forecasts range from $20.00 to $38.00. On average, t...
Who are Translate Bio's key executives?
Translate Bio's management team includes the following people: Ilan Danieli , Chief Executive Officer & Director Ahmed Zaki Sabet , Chief Operat...
What is Craig J. Tuttle's approval rating as Translate Bio's CEO?
13 employees have rated Translate Bio CEO Craig J. Tuttle on Glassdoor.com . Craig J. Tuttle has an approval rating of 5% among Translate Bio's em...
Who are some of Translate Bio's key competitors?
Some companies that are related to Translate Bio include QIAGEN (QGEN) , Qiagen (QGEN) , Repligen (RGEN) , Neurocrine Biosciences (NBIX) , Exe...
What other stocks do shareholders of Translate Bio own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Translate Bio investors own include Inovio Pharmaceuticals...
When did Translate Bio IPO?
(TBIO) raised $100 million in an IPO on Thursday, June 28th 2018. The company issued 7,700,000 shares at $12.00-$14.00 per share. Citigroup, Leerin...
What is Translate Bio's stock symbol?
Translate Bio trades on the NASDAQ under the ticker symbol "TBIO."
Recently Viewed Tickers
Bio-Rad Laboratories Inc. Cl A
Visit a quote page and your recently viewed tickers will be displayed here.
About Translate Bio
Bio-Rad Laboratories, Inc. engages in the development and production of specialty chemicals used in biochemical, pharmaceutical, and other life science research applications. It operates through the Life Sciences and Clinical Diagnostics segments.
Translate Bio (NASDAQ:TBIO) Frequently Asked Questions
Precipio, Inc.is a cancer diagnostics and reagent technology company, which provides diagnostic products and services to the oncology market. Its products include ICP, HemeScreen, and IV-Cell, and services include primary diagnostic, SmartPath, SmartGen, HemeScreen Panel, and ICE COLD-PCR.
About Vyant Bio
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Translate Bio in the last twelve months. There are currently 6 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" Translate Bio stock.
3.5 Analyst's Opinion
Vyant Bio, Inc. is emerging as an advanced biotechnology drug discovery company. The firm is focused on human-powered scientific and technology-based systems to de-risk and accelerate the discovery and development of therapeutics for biopharma partners, as well as for its proprietary pipeline.
Is Vyant Bio a buy right now?
Vyant Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
How has Vyant Bio's stock price been impacted by Coronavirus?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vyant Bio in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" Vyant Bio stock. View analyst ratings for Vyant Bio or view top-rated stocks.
Are investors shorting Vyant Bio?
Vyant Bio's stock was trading at $3.59 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, VYNT shares have decreased by 69.1% and is now trading at $1.11. View which stocks have been most impacted by COVID-19.
When is Vyant Bio's next earnings date?
Vyant Bio saw a drop in short interest in January. As of January 15th, there was short interest totaling 113,600 shares, a drop of 18.7% from the December 31st total of 139,700 shares. Based on an average daily trading volume, of 142,200 shares, the days-to-cover ratio is presently 0.8 days.
How were Vyant Bio's earnings last quarter?
Vyant Bio is scheduled to release its next quarterly earnings announcement on Thursday, March 3rd 2022. View our earnings forecast for Vyant Bio.
About Palisade Bio
Vyant Bio, Inc. (NASDAQ:VYNT) posted its quarterly earnings data on Thursday, November, 11th. The company reported ($0.15) earnings per share (EPS) for the quarter, meeting the Thomson Reuters' consensus estimate of ($0.15). The business earned $1.51 million during the quarter, compared to analysts' expectations of $2.19 million.
3.5 Analyst's Opinion
Palisade Bio, Inc. is a biopharmaceutical company, which engages in the development of oral therapies that help patients with acute and chronic gastrointestinal complications stemming from post-operative digestive enzyme damage.
Is Palisade Bio a buy right now?
Palisade Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Are investors shorting Palisade Bio?
2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Palisade Bio in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Palisade Bio stock. View analyst ratings for Palisade Bio or view top-rated stocks.
When is Palisade Bio's next earnings date?
Palisade Bio saw a increase in short interest in the month of January. As of January 15th, there was short interest totaling 169,200 shares, an increase of 50.8% from the December 31st total of 112,200 shares. Based on an average trading volume of 180,600 shares, the days-to-cover ratio is currently 0.9 days.
How were Palisade Bio's earnings last quarter?
Palisade Bio is scheduled to release its next quarterly earnings announcement on Monday, March 28th 2022. View our earnings forecast for Palisade Bio.
What price target have analysts set for PALI?
Palisade Bio, Inc. (NASDAQ:PALI) released its quarterly earnings data on Monday, November, 15th. The company reported $0.42 EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.36) by $0.78. View Palisade Bio's earnings history.
